Status:
RECRUITING
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Proteinuric Kidney Disease
Eligibility:
All Genders
10-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric...
Eligibility Criteria
Inclusion
- Key
- APOL1 genotype of G1/G1, G2/G2, or G1/G2
- Proteinuric kidney disease
- Key
Exclusion
- Solid organ or bone marrow transplant
- Uncontrolled hypertension
- History of diabetes mellitus
- Known underlying cause of kidney disease including but not limited to sickle cell disease
- Other protocol defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
March 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
466 Patients enrolled
Trial Details
Trial ID
NCT05312879
Start Date
March 30 2022
End Date
June 30 2026
Last Update
December 12 2025
Active Locations (318)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Kidney Research
Alabaster, Alabama, United States, 35007
2
EmVenio Research - Mobile Unit - Birmingham
Birmingham, Alabama, United States, 35210
3
Cardiology, P.C.
Birmingham, Alabama, United States, 35211
4
Children's Hospital of Alabama
Birmingham, Alabama, United States, 35233